Malignant Tumors of the Lung

by Jean-Paul Sculier & Willard A. Fry

Ed Springer, Berlin, 2003

ISBN 3-540-43887-4

Introduction. JP Sculier and W Fry

Epidemiology, biology and pathology

01 Molecular and cell biology. F Hirsch & W Franklin (University of Colorado Medical Center, Denver, CO, USA)

02 Clinically useful biomarkers. Jean-Louis Pujol, William Jacot, Jean-Marie Boher, Xavier Quantin. Montpellier Academic Hospital, and "Languedoc Mutualité" New Technologies, Montpellier, France.

03 Pathology. E Brambilla (CHU de Grenoble , France) & William Travis (Armed Forces Institute of Pathology,Washington, DC, USA)

04 Epidemiology. Kevin M. Dineen and Gerard A. Silvestri (Medical University of South Carolina, Charleston, SC, USA)

05 Lung cancer and tobacco: historical issues, epidemiology, and intervention. Thomas P. Houston (American Medical Association, Chicago,IL, USA)

06 Professional risks and environment factors. Paolo Boffetta (International Agency for Research on Cancer, Lyon, France)

Early detection, diagnosis and staging

07 Radiological screening. Claudia Henschke (New York Presbyterian Hospital – Cornell Medical Center Cornell Medical Center, New York, NY, USA)

08 Lung cancer screening: the role of bronchoscopy. JA Nakhosteen (Research Institute for Diagnosis and Treatment of Early Lung Cancer, Bochum, Germany) & V Ninane (Hôpital Saint-Pierre, Brussels, Belgium)

09 Clinical presentation. Gregory A. Master and Kyong Oh (Evanston Northwestern Healthcare, Feinberg School of Medicine, Northwestern University, USA)

10 Differential diagnosis. N Schoenfeld (Chest Hospital Heckeshorn, Berlin, Germany)

11 Imaging. Maureen White (Evanston Northwestern Healthcare, Evanston, IL, USA)

12 PET scan. Johan F. Vansteenkiste and Sigrid G. Stroobants (Respiratory Oncology Unit (Pulmonology) and PET-centre (Nuclear Medicine), University Hospital Gasthuisberg, Catholic University Leuven, Belgium)

13 Pathological diagnosis obtention. V Ninane (Hôpital Saint-Pierre, Brussels, Belgium)

14 Mediastinal staging. G Massard (Hôpital Civil, Strasbourg, France)

15 Assessment of operability and resectability in lung cancer. W A Fry (Northwestern University Medical School, Chicago, USA)

16 TNM staging. M J Liptay (Evanston Northwestern Healthcare, Evanston, IL, USA), C Mascaux and JP Sculier (Institut Jules Bordet, Brussels, Belgium)


Non small cell lung cancer

17 Surgery T Rami-Porta and Mireia Serra-Mitjans (Hospital Mutua de Terrassa, Terrassa, Spain)

18 Neoadjuvant treatments in resectable non-small cell lung cancer. V Westeel and A Depierre (Centre Hospitalier Régional, Besançon, France)

19 Adjuvant treatments in resectable NSCLC. H Doubre, C Le Pechoux and T Le Chevalier(Institut Gustave Roussy, Villejuif, France)

20 Elective radiotherapy. David G. Payne (Princess Margaret Hospital, Toronto, ONT,Canada)

21 Combined modality therapy for unresectable non-small cell lung cancer. Lisa T. Hazard and William T. Sause (Latter Day Saints Hospital, Salt Lake City, UT, USA)

22 Chemotherapy for advanced disease non-small cell lung cancer. T Berghmans & JP Sculier (Institut Jules Bordet, Brussels, Belgium)

23 Salvage therapy. E Quoix and B Mennecier (Hôpitaux Universitaires de Strasbourg Strasbourg, France)

Small cell lung cancer

24 Limited disease. P Van Houtte, M Roelandts (Institut Jules Bordet, Brussels, Belgium), M Cappello (Erasme Hospital, Brussels, Belgium) and F Mornex (Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France)

25 Extensive disease. N Hanna and LH Einhorn (University of Indiana, Indianapolis,IN, USA)

26 Surgery for small cell lung cancer. JP Sculier, P Lothaire (Institut Jules Bordet, Brussels, Belgium), T Bosschaerts and V Ninane (Hôpital Saint-Pierre, Brussels, Belgium)

27. Preventive cranial irradiation. AP Meert and M Paesmans (Institut Jules Bordet, Brussels, Belgium)

28. Salvage therapy. E. Smit and Postmus (Free University Hospital, Amsterdam, The Netherlands)


29 Endoscopic treatments. H Kato, N Ikeda, T Okunaka, K Furukawa and M Tsuboi (Tokyo Medical College, Tokyo, Japan)

30 Biological treatments (SCLC & NSCLC). S Shingal, JB Schrager and L L Kaiser (Hospital of the University of Pennsylvania, Philadelphia,PA, USA)

Complications and supportive care

31 Bone marrow aplasia. T Berghmans & JP Sculier (Institut Jules Bordet, Brussels, Belgium)

32 Management of superior vena cava syndrome. N Perez,CH Marquette, JP Beregi, D Collet and JJ Lafitte (Hôpital Albert Calmette, Lille, France)

33 Airway obstruction. RM Huber and D Stratakis (Klinikum Innenstadt, Munich, Germany)

34 Malignant pleural effusion. P Van Schil and Paul Germonpré (University Hospital of Antwerp, Antwerp, Belgium)

35 Symptomatic treatment. MF Muers (Killingbeck Hospital, Leeds, UK)

36 End-of-Life Care in Patients with Lung Cancer. J von Roenn and JF Brandman (Northwestern Memorial Hospital, Chicago, IL,USA)


37 NSCLC prognosis. K S Albain and M Quejada (Loyola University Medical Center, Maywood, IL, USA)

38 SCLC prognosis. M Paesmans (Institut Jules Bordet, Brussels, Belgium)